Advanced maternal age as a sole indication for genetic amniocentesis; Risk-benefit analysis based on a large database reflecting the current common practice

Journal of Perinatal Medicine

Volumn 37, Issue 2, 2009, Pages 99-102

  Bornstein, Eran ^a   Lenchner, Erez ^b   Donnenfeld, Alan ^c   Barnhard, Yoni ^d   Seubert, David ^a   Divon, Michael Y ^d  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c Genzyme Genetics   (United States)

^d LENOX HILL HOSPITAL   (United States)

Author keywords

Advanced maternal age; Amniocentesis; Down's syndrome; Prenatal diagnosis; Trisomy 21

Indexed keywords

ADULT; AMNIOCENTESIS; ARTICLE; DATA BASE; FEMALE; FETUS; FETUS WASTAGE; GENETIC SCREENING; HUMAN; MATERNAL AGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; TRISOMY 21;

ADULT; AMNIOCENTESIS; DOWN SYNDROME; FEMALE; FETAL DEATH; HUMANS; MATERNAL AGE; PREGNANCY; PRENATAL DIAGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 59449098655     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/JPM.2009.032     Document Type: Article

References (18)

1. Alexander D, Lowe CU, Seigel D, Bryla D. Risks of amniocentesis. Lancet. 1979;15;2:577-8.
2. American College of Obstetricians and Gynecologists Committee on Practice Bulletins Obstetrics. ACOG Practice Bulletin. Screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007;109:217-27.
3. An assessment of the hazards of amniocentesis. Report to the medical research council by their working party on amniocentesis. Br J Obstet Gynaecol. 1978;85:1-41.
4. Benn PA, Egan JF, Fang M, Smith-Bindman R. Changes in the utilization of prenatal diagnosis. Obstet Gynecol. 2004;103:1255-60.
5. Chasen ST, McCullough LB, Chervenak FA. Is nuchal translucency screening associated with different rates of invasive testing in an older obstetric population? Am J Obstet Gynecol. 2004;190:769-74.
6. Chorionic villus sampling and amniocentesis: recommendations for prenatal counseling. Centers for disease control and prevention. MMWR Recomm Rep. 1995;44:1-12.
7. Eddleman KA, Malone FD, Sullivan L, Dukes K, Berkowitz RL, Kharbutli Y, et al. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol. 2006;108:1067-72.
8. Henry GP, Britt DW, Evans MI. Screening advances and diagnostic choice: the problem of residual risk. Fetal Diagn Ther. 2008;23:308-15. Epub 2008 Apr 14.
9. Hook EB. Rates of chromosome abnormalities at different maternal ages. Obstet Gynecol. 1981;58:282-5.
10. Hook EB, Chambers GM. Estimated rates of Down syndrome in live births by one year maternal age intervals for mothers aged 20-49 in a New York State study: implications of the risk figures for genetic counseling and cost-benefit analysis of prenatal diagnosis programs. Birth Defects Orig Artic Ser. 1977;13:123-41.
11. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First- and Second-Trimester Evaluation of Risk (FASTER) Research consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med. 2005;353:2001-11.
12. Mennuti MT. Risks of second-trimester amniocentesis: why all the fuss 30 years later? Obstet Gynecol. 2008;111:586-8.
13. National Insitute of Child Health and Human Development, National Registry for Amniocentesis Study Group. Midtrimester amniocentesis for prenatal diagnosis. Safety and accuracy. JAMA. 1976;236:1471-6.
14. Odibo AO, Gray DL, Dicke JM, Stamilio DM, Macones GA, Crane JP. Revisiting the fetal loss rate after second-trimester genetic amniocentesis: a single center's 16-year experience. Obstet Gynecol. 2008;111:589-95.
15. Resta RG. Changing demographics of advanced maternal age (AMA) and the impact on the predicted incidence of Down syndrome in the United States: implications for prenatal screening and genetic counseling. Am J Med Genet. 2005;133:31-6.
16. Seeds JW. Diagnostic mid trimester amniocentesis: how safe? Am J Obstet Gynecol. 2004;191:607-16.
17. Simpson NE, Dallaire L, Miller JR, Siminovich L, Hamerton JL, Miller J, et al. Prenatal diagnosis of genetic disease in Canada: report of a collaborative study. Can Med Assoc J. 1976;115:739-48.
18. Tabor A, Philip J, Madsen M, Bang J, Obel EB, Nørgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet. 1986;1:1287-93.